**Clinical interpretation of *KCNH2* variants using a robust PS3/BS3 functional patch clamp**

**assay**

Kate L. Thomson,[1] Connie Jiang,[2,3] Ebony Richardson,[4,5] Dominik S. Westphal,[6,7,8] Tobias

Burkard,[9] Cordula M. Wolf,[8,9,10] Matteo Vatta,[11] Steven M. Harrison,[12] Jodie Ingles,[4,5] Connie

R. Bezzina,[8,13] Brett M. Kroncke,[14] Jamie I. Vandenberg,[3,15,*] and Chai-Ann Ng[3,15,**]

[1]Oxford Genetics Laboratories, Churchill Hospital, Oxford, UK. [2]Faculty of Medicine and Health,

UNSW Sydney, Kensington, NSW, Australia. [3]Mark Cowley Lidwill Research Program in Cardiac

Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia. [4]Centre for

Population Genomics, Garvan Institute of Medical Research and UNSW Sydney, Sydney, Australia.

[5]Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia.

[6]Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine and Health, Technical

University of Munich, Munich, Germany. [7]Department of Internal Medicine I, Klinikum Rechts der

Isar, School of Medicine and Health, Technical University of Munich, Germany. [8]European Reference

Network for Rare, Low Prevalence and Complex Diseases of the Heart: ERN GUARD-Heart.

[9]Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich,

Technical University of Munich, School of Medicine and Health, Munich, Germany. [10]DZHK (German

Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. [11]Invitae

Corporation, San Francisco, CA, USA. [12]Ambry Genetics, Aliso Viejo, CA, USA. [13]Department of

Experimental Cardiology, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam

UMC, Amsterdam, the Netherlands. [14]Vanderbilt Center for Arrhythmia Research and Therapeutics,

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center,

Nashville, TN, USA. [15]School of Clinical Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.

Correspondence should be addressed to

*Jamie I. Vandenberg MBBS, Ph.D, Victor Chang Cardiac Research Institute, 405 Liverpool St,

Darlinghurst, NSW 2010, Australia. E-mail: j.vandenberg@victorchang.edu.au; Tel: +61 2

9295 8687 and

**Chai-Ann Ng, Ph.D., Victor Chang Cardiac Research Institute, 405 Liverpool St,

Darlinghurst, NSW 2010, Australia. E-mail: c.ng@victorchang.edu.au; Tel: +61 2 9295 8687

**Summary**

Long QT syndrome (LQTS), caused by the dysfunction of cardiac ion channels, increases the

risk of sudden death in otherwise healthy young people. For many variants in LQTS genes

there is insufficient evidence to make a definitive genetic diagnosis. We have established a

robust functional patch clamp assay to facilitate classification of missense variants in *KCNH2*,

one of the key LQTS genes. A curated set of 30 benign and 30 pathogenic missense variants

were used to establish the range of normal and abnormal function. The extent to which

variants reduced protein function was quantified using Z-scores; the number of standard

deviations from the mean of the normalised current density of the set of benign variant

controls. A Z-score of −2 defined the threshold for abnormal loss-of-function, which

corresponds to 55% wild-type function. More extreme Z-scores were observed for variants

with a greater loss-of-function effect. We propose that the Z-score for each variant can be

used to inform the application and weighting of abnormal and normal functional evidence

criteria (PS3 and BS3) within the American College of Medical Genetics and Genomics (ACMG)

variant classification framework. The validity of this approach was demonstrated using a

series of 18 *KCNH2* missense variants detected in a childhood onset LQTS cohort, where the

level of function assessed using our assay correlated to the Schwartz score (a scoring system

used to quantify the probability of a clinical diagnosis of LQTS[1]) and the length of the QTc

interval.

Long QT syndrome (LQTS; MIM:192500) is a rare genetic disorder caused by variants

in genes which encode cardiac ion channel proteins. Abnormal variants in these genes lead

to cardiac ion channel dysfunction, which can result in cardiac arrhythmia and an increased

risk of sudden death, often with no prior symptoms. Genetic testing is recognised as a key

component of patient management and is recommended by clinical guidelines.[2] Establishing

a genetic diagnosis can inform clinical management and treatment strategies, provide greater

accuracy in assessing prognosis, and enable reproductive counselling. Importantly, as not all

individuals with a pathogenic variant present with clinical signs or symptoms of LQTS, where

a genetic diagnosis is confirmed in an affected individual, genetic testing can be offered to

family members, to identify those at risk. The perceived clinical importance of making a

presymptomatic genetic diagnosis of LQTS is highlighted by the inclusion of the key causal

genes in the ACMG list for reporting of secondary findings in clinical exome and genome

sequencing.[3]

Current genome sequencing technologies enable more comprehensive genetic

analysis to be performed cost effectively and genetic testing has become more widely

adopted for LQTS. While this has led to an increase in the proportion of patients with a genetic

diagnosis, the interpretation of genetic test results remains challenging. Due to lack of

definitive evidence for pathogenicity, many missense variants detected in LQTS genes are

classified as variants of uncertain clinical significance (VUS), which are not actionable

clinically. High numbers of VUS can reduce the clinical utility of genetic testing.

In a recent study,[4] we demonstrated the utility of a high throughput patch-clamp assay

to assess the functional consequences of a set of 31 missense variants in the *KCNH2* gene

(Table 1). [4,5] This gene encodes Kv11.1, a protein component of the voltage-gated potassium

ion channel, which is responsible for the rapid delayed rectifier current ($I_{Kr}$). Loss-of-function

variants in this gene are one of the most common causes of LQTS.[5] This assay, which

quantifies the current density at −50mV as a surrogate for $I_{Kr}$ current in heart cells, was able

to clearly discriminate between missense variants with normal and abnormal loss-of-function

(LoF).[4]

We previously illustrated how data from this assay could be used to inform clinical

variant classification using the American College of Medical Genetics and the Association for

Molecular Pathology (ACMG/AMP)  framework, providing statistical support for application

of the functional evidence (PS3 and BS3 criteria) with 'supporting' or 'moderate' weighting.[4]

In this study, we expand on our previous work,[4] undertaking functional analysis of additional

variants to give a total of 30 pathogenic and 30 benign variant controls (Table 1). The 30

benign / likely benign variant controls were selected on the basis of their minor allele

frequency (MAF) in the Genome Aggregation database (gnomAD;maximum population

filtering allele frequency[6] [PopMax FAF] greater than $5x10^{-5}$, see supplementary materials).

The advantage of using a larger number of benign variant controls, selected based on the

MAF, is that we were able to sample a broader range of biological and experimental variation,

and more clearly define a range for normal function measured by patch clamp

electrophysiology (Figure 1 and Figure S2). Using our assay, the functionally normal range was

defined by a Z-score within ±2 of the mean normalised current density determined from 30

benign control variants. The functionally abnormal LoF range was defined by a Z-score of −2

or below, corresponding to a variant having less than 55% of normal function, a clinically

relevant threshold consistent with protein haploinsufficiency.[7]

In our previous study, the 17 pathogenic variant controls had various levels of reduced

function. In this study, we included an additional 13 pathogenic variant controls (Table 1 and

Table S1) to increase the statistical power of the assay (Table 2). The experimental procedure

is described in the supplementary materials. Four out of the 30 pathogenic variant controls

were observed in gnomAD, however, with the exception of the Finnish founder variant,

p.(Leu552Ser),[7,8] all had a minor filtering allele frequency lower than the threshold selected

for benign control variants (Table S1). All 30 pathogenic variant controls had Z-scores of −2 or

less (Figure 1 and Table S3). Assay performance was evaluated using the approach

recommended by the Clinical Genome Resource (ClinGen) Sequence Variant Interpretation

(SVI) Working Group[9]; the odds of pathogenicity (OddsPath) were determined to be 30 for

abnormal function (PS3) and 0.034 for normal BS3 function (Table 2).

To integrate this functional data into variant classification, and to take into consideration

the various levels of reduced function revealed by this assay, we considered a graded

evidence scale weighted according to the severity of the LoF determined by the Z-score. Using

this scale, variants with Z-score between −2 and −3 (mild LoF), −3 and −4 (moderate LoF) and

less than −4 (severe LoF) could be categorised as PS3_supporting, PS3_moderate or

PS3_strong, respectively. It is important to note that this *in vitro* cell model system may not

fully reflect protein function *in vivo* and might not capture all abnormal LoF. Taking into

consideration these limitations, we proposed that normal function variants with a Z-score

between 0 and 1 or −1 could be classified as BS3_moderate and Z-score between 1 and 2 or

−1 and −2 as BS3_supporting (Figure 1).

To investigate the utility of our approach, the functional evidence level determined from

this assay was applied to enhance the classification of 18 *KCNH2* missense variants detected

by Westphal *et al* in children with suspected LQTS.[10] Evidence of abnormal LoF was found for

14 missense variants (Figure 2A, yellow and brown circles and Table S3). Four variants were

in the range of normal function (Table S3). Two of these variants (p.Asp259Asn and

p.Thr983Ile), were detected in children who had been included in the cohort due to a family

history sudden cardiac death, but had normal QTc and a Schwartz score of less than 1 (low

probability of LQTS[1]) (Figure 2C). The p.Val409Ile variant was found in a child with a Schwartz

score of 2 (intermediate probability of LQTS[1]). The p.Pro393Leu variant was found in a child

who was also heterozygous for the p.Arg176Trp variant, a possible risk allele,[11] which has

been described as a founder variant in the Finnish population.[12]

Considering data from 32 paediatric LQTS cases in this cohort who were heterozygous for

one of these *KCNH2* missense variants, there was a negative correlation between the Z-score

determined by this assay and Schwartz score (r = −0.74 (Figure 2B) with a R2 of 0.54 from

linear regression). Overall, the variants that were determined by our assay to have severe LoF

were detected in individuals with a more severe clinical phenotype (measured by Schwartz

score) and a more prolonged QTc, this is consistent with previous observations.[13,14] The

variant classifications in Westphal *et al*[10] were revised by applying the level of functional

evidence at the strength determined by the Z-scores (Table S3). Considering this additional

evidence, the classification of one variant (p.Leu697His) was upgraded from VUS to likely

pathogenic after PS3 was applied at strong level (Table S2).

Overall, the findings of our study indicate that the functional evidence produced by this

validated assay is extremely valuable for the interpretation of *KCNH2* missense variants in the

context of LQTS. However, functional data from this assay should not be used as sole evidence

to classify a variant as pathogenic or benign, but should be considered in the context of other

evidence, as outlined in the ACMG/AMP framework.[15]

At present, we have not extensively examined the functional range of so-called risk

alleles, which display incomplete penetrance and may only have pathogenic potential in the

presence of other environmental or genetic risk factors. For example, the p.(Arg176Trp)

variant, which was detected in the Westphal *et al* childhood onset LQTS cohort, has been

reported as founder variant in the Finnish population[8] and reported to be enriched in

individuals referred for LQTS genetic testing but lacking a molecular diagnosis.[16] The

frequency of this variant in the gnomAD European (non-Finnish) population was higher than

the threshold used to select benign variant controls for this study, however, it was

determined by the assay to have a mild LoF effect (Z-score −2.75); these findings are

consistent with this being a variant with low or incomplete penetrance. Further studies may

provide additional functional evidence which might help clarify the pathogenic potential of

this class of variant.

In conclusion, this patch clamp assay, which used extensively characterised variant

controls to calibrate thresholds for normal and abnormal loss-of-function missense variants

in the *KCNH2* gene, provides reliable functional evidence that can be incorporated into clinical

variant classification. This has potential to reduce uncertainty in variant interpretation in this

clinically important gene.

**Data and code availability**

The current traces from the patch clamp electrophysiology that support the findings of this

study are available as csv files upon request. The corresponding analysis scripts for patch-

clamp experiments are available at https://git.victorchang.

edu.au/projects/SADA/repos/syncropatch_automated_analysis/browse.

**Supplemental information**

Table S1– Summary of *KCNH2* benign and pathogenic variant controls.

Table S2 – Summary of *KCNH2* variants reclassification after functional assessment.

Table S3 – Summary of Z-score and patch clamp data for all variants.

Table S4 – Summary of maximum credible population allele frequency.

**Acknowledgements**

This work was funded by an NSW Cardiovascular Disease Senior Scientist grant (J.I.V.), an

National Health and Medical Research Council Principal Research Fellowship (J.I.V.), MRFF

Genomics Health Futures Mission grant (J.I.V. and C.A.N). We also acknowledge support

from the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW

Government.

**Author contributions**

Conceptualization: K.L.T., J.I.V., C.A.N.; Data curation: K.L.T., E.R., C.A.N.; Formal Analysis:

K.L.T., C.J., E.R., D.S.W., T.B., C.M.W., M.V., S.M.H., J.I.V., C.A.N.; Funding acquisition: J.I.V.;

Methodology: K.L.T., C.J., E.R., J.I., J.I.V., C.A.N.; Writing – original draft: K.L.T., J.I.V., C.A.N.;

Writing – review & editing: K.L.T., E.R., D.S.W., T.B., C.M.W., M.V., S.M.H., J.I., C.R.B., B.M.K.,

J.I.V., C.A.N.

**Declaration of interests**

M.V. is an employee and stockholder of Invitae Corporation. The other authors declare no

competing interests.

**Figure Legend**

**Figure 1: Establishment of graded functional evidence strength based on the Z-score determined**

**from benign and pathogenic variant controls.** (A) The cut-off for functionally normal (blue circles) and

abnormal (brown circles) was determined to be 55% of WT using 2 standard deviations below the

mean of all benign controls. (B) The establishment of evidence strength for functional data based on

the Z-score of –2 by using 30 benign variant controls. The level of evidence strength was graded based

on the Z-score where normal function for BS3 at moderate (between 0 and ± 1) or supporting

(between 1 and 2 or –1 and –2). The abnormal function for PS3 at supporting (between –2 to –3),

moderate (between –3 to –4) and strong (less than –4). The comparison of benign variant controls

was made against known benign / likely benign variants classified by two other diagnostic laboratories.

All the 30 pathogenic variant controls used were found to have function less than the benign variant

controls (see Table S3).

**Figure 2: Missense *KCNH2* variants from children with long QT syndrome.** (A) The functional

assessment of these variants using patch-clamp assay. Blue region indicates the functionally normal

range determined from a set of 30 benign variant controls. Variants are colour-coded to indicate the

Z-score: blue for Z-score between 0 and ±1, light blue for Z-score between 1 and 2 or −1 and −2, yellow

for Z-score between −2 to −3, orange for Z-score between −3 to −4 and brown for Z-score less than −

4. Variants that were downgraded to VUS in Westphal $et$ $al$[10] are indicated by #. The heterozygous

variant p.(Pro393Leu) with a risk allele p.(Arg176Trp) is indicated by red outline. (B) The correlation of

Schwartz score from children that have these variants and the corresponding function of the variant

assessed by patch clamp assay. Region of Schwartz score above 3.5 is highlighted to indicate the

severity of the LQT clinical phenotype. The Pearson r for this correlation is −0.74 and the $R^2$ of linear

regression is 0.54 with p=0.0007. The Schwartz score for the compound heterozygous p.(Pro393Leu)

with a risk allele p.(Arg176Trp) was not included. Data is presented as mean +/- s.e.m. (C) The

correlation of QTc and the corresponding function of the variant assessed by patch clamp assay.

Region of QTc above 480ms is highlighted. The Pearson r for this correlation is −0.76 and the $R^2$ of

linear regression is 0.58 with p=0.0004. The QTc for the compound heterozygous p.(Pro393Leu) with

a risk allele p.(Arg176Trp) was not included. Data is presented as mean +/- s.e.m.

**Table 1: Summary of the 60 variant controls.**

| Benign/Likely Benign | | |
|---|---|---|
| This study | 17 | Total of 30 |
| Jiang *et al* 2022 | 13 | |
| **Pathogenic/Likely pathogenic** | | |
| This study | 13 | Total of 30 |
| Jiang *et al* 2022 | 17 | |

The details for each of the variant controls are available in Table S1.

**Table 2: Odds of Pathogenicity (OddsPath).**

| # Classified | | Proportion pathogenic (Prior, $P_1$) | Assay result | | | | "+1 proportions" (Posterior, $P_2$) | | OddsPath=[$P_2$ x (1- $P_1$)] / [(1- $P_2$) x $P_1$] | |
|---|---|---|---|---|---|---|---|---|---|---|
| **Pathogenic** | **Benign** | | **Total assay Abnormal** | **Total assay Normal** | **True Path in Abnormal** | **True Path in Normal** | **Proportion Path in Abnormal** | **Proportion Path in Normal** | **Pathogenic (Evidence strength equivalent)** | **Benign (Evidence strength equivalent)** |
| **Total** | | | | | | | | | | |
| 30 | 30 | 0.50 | 31 | 29 | 30 | 0 | 0.97 | 0.03 | 30.0 (PS3_Strong) | 0.034 (BS3_Strong) |
| **60** | | | | | | | | | | |

Modified from Fayer *et al* 2021.[17] Note: this estimate "adds 1.0" to the numerator and denominator to do a calculation.

**References**

1.  Schwartz, P.J., and Crotti, L. (2011). QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation *124*, 2181-2184. 10.1161/CIRCULATIONAHA.111.062182.

2.  Wilde, A.A.M., Semsarian, C., Marquez, M.F., Shamloo, A.S., Ackerman, M.J., Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al. (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace *24*, 1307-1367. 10.1093/europace/euac030.

3.  Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H., Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2022). ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med *24*, 1407-1414. 10.1016/j.gim.2022.04.006.

4.  Jiang, C., Richardson, E., Farr, J., Hill, A.P., Ullah, R., Kroncke, B.M., Harrison, S.M., Thomson, K.L., Ingles, J., Vandenberg, J.I., and Ng, C.A. (2022). A calibrated functional patch-clamp assay to enhance clinical variant interpretation in KCNH2-related long QT syndrome. Am. J. Hum. Genet. *109*, 1199-1207.

5.  Adler, A., Novelli, V., Amin, A.S., Abiusi, E., Care, M., Nannenberg, E.A., Feilotter, H., Amenta, S., Mazza, D., Bikker, H., et al. (2020). An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation *141*, 418-428. 10.1161/CIRCULATIONAHA.119.043132.

6.  Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y., Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., and Ware, J.S. (2017).

Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med *19*, 1151-1158. 10.1038/gim.2017.26.

7.      Piippo, K., Laitinen, P., Swan, H., Toivonen, L., Viitasalo, M., Pasternack, M., Paavonen, K., Chapman, H., Wann, K.T., Hirvela, E., et al. (2000). Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J. Am. Coll. Cardiol. *35*, 1919-1925. 10.1016/s0735-1097(00)00636-7.

8.      Fodstad, H., Swan, H., Laitinen, P., Piippo, K., Paavonen, K., Viitasalo, M., Toivonen, L., and Kontula, K. (2004). Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann. Med. *36 Suppl 1*, 53-63. 10.1080/17431380410032689.

9.      Brnich, S.E., Abou Tayoun, A.N., Couch, F.J., Cutting, G.R., Greenblatt, M.S., Heinen, C.D., Kanavy, D.M., Luo, X., McNulty, S.M., Starita, L.M., et al. (2020). Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med *12*, 3. 10.1186/s13073-019-0690-2.

10.     Westphal, D.S., Burkard, T., Moscu-Gregor, A., Gebauer, R., Hessling, G., and Wolf, C.M. (2020). Reclassification of genetic variants in children with long QT syndrome. Mol Genet Genomic Med *8*, e1300. 10.1002/mgg3.1300.

11.     Giudicessi, J.R., Roden, D.M., Wilde, A.A.M., and Ackerman, M.J. (2018). Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation *137*, 619-630. 10.1161/CIRCULATIONAHA.117.030142.

12.   Marjamaa, A., Salomaa, V., Newton-Cheh, C., Porthan, K., Reunanen, A., Karanko, H., Jula, A., Lahermo, P., Vaananen, H., Toivonen, L., et al. (2009). High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann. Med. *41*, 234-240. 10.1080/07853890802668530.

13.   Aizawa, T., Wada, Y., Hasegawa, K., Huang, H., Imamura, T., Gao, J., Kashiwa, A., Kohjitani, H., Fukuyama, M., Kato, K., et al. (2023). Non-missense variants of KCNH2 show better outcomes in type 2 long QT syndrome. Europace *25*, 1491-1499. 10.1093/europace/euac269.

14.   Moss, A.J., Zareba, W., Kaufman, E.S., Gartman, E., Peterson, D.R., Benhorin, J., Towbin, J.A., Keating, M.T., Priori, S.G., Schwartz, P.J., et al. (2002). Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation *105*, 794-799.

15.   Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med *17*, 405-424. 10.1038/gim.2015.30.

16.   Vatta, M., Truty, R., Garcia, J., Callis, T.E., Hatchell, K., Rojahn, S., Morales, A., Aradhya, S., and Nussbaum, R. (2021). Common Variants in KCNE1, KCNH2, and SCN5A May Impact Cardiac Arrhythmia Risk. Circ Genom Precis Med *14*, e003206. 10.1161/CIRCGEN.120.003206.

17.   Fayer, S., Horton, C., Dines, J.N., Rubin, A.F., Richardson, M.E., McGoldrick, K., Hernandez, F., Pesaran, T., Karam, R., Shirts, B.H., et al. (2021). Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain

significance in BRCA1, TP53, and PTEN. Am. J. Hum. Genet.

10.1016/j.ajhg.2021.11.001.

Figure 1

Figure 2